Oxford PharmaGenesis has recently joined OBN, the UK membership organization for innovative life science R&D companies in the golden triangle of Oxford, Cambridge and London – and beyond. Chris Winchester, Managing Director of Oxford PharmaGenesis, comments, “We are proud to be part of a support network for emerging life-science companies and offer our communications expertise.”
OBN is on a rapidly ascending trajectory, increasing its membership from 240 in 2013 to over 360 members today. By connecting emerging leaders in life science R&D, the organization makes a unique contribution to the UK biopharmaceutical industry. “I am delighted to welcome Oxford PharmaGenesis to OBN’s membership; I believe they can add significant value to our members’ communication efforts,” says Jon Rees, CEO of OBN.
Help with early planning
At Oxford PharmaGenesis, we aim to strengthen our links with local biotech and medtech companies, learning more about their needs and explaining the value of HealthScience communications. “It has never been more important to define the intended clinical use of a product early in development and to understand its anticipated value to patients and healthcare systems,” observes Richard White, Commercial Director of Oxford PharmaGenesis, “and we can help OBN members do just that.”